Latest News & Updates
Breaking News
22 hours ago
Vaibhavi M.
Novartis Acquires Myricx Bio in $1.5bn Deal to Add NMTi ADC Payload Platform
Pharma Now Editorial Team
ReproNovo Achieves First Dosing Milestone in EU Phase 2 NORDIC Trial for RPN-002 in ART
Pharma Now Editorial Team
Other trending news you may like to read
Moleculin Releases Preliminary MIRACLE Trial Data for Annamycin in Relapsed or Refractory AML
Moleculin releases preliminary Phase 2/3 MIRACLE trial data for Annamycin in R/R AML; n=45 cohort has not yet achieved statistical significance.
Vaibhavi M.
Cipla Appoints Sushrut Kulkarni as Global Chief of Integrated Product Development
Cipla names Sushrut Kulkarni Global Chief of Integrated Product Development, consolidating R&D and manufacturing pipeline leadership under one role.
Vaibhavi M.
Glenmark Launches Generic Olanzapine Injection in US After ANDA Approval for $25.4M Market
Glenmark launches FDA-approved generic Olanzapine for Injection in the US, entering a $25.4M market as a therapeutic equivalent to Zyprexa IM.
Vaibhavi M.
Novartis Acquires Myricx Bio in $1.5bn Deal to Add NMTi ADC Payload Platform
Novartis acquires Myricx Bio for up to $1.5bn, adding an NMTi ADC payload platform targeting resistance to current conjugate classes.
Pharma Now Editorial Team
